AbbVie Inc. (ABBV)

92.26
NYSE : Health Technology
Prev Close 92.68
Day Low/High 92.05 / 93.33
52 Wk Low/High 83.19 / 125.86
Avg Volume 5.60M
Exchange NYSE
Shares Outstanding 1.51B
Market Cap 140.34B
EPS 3.30
P/E Ratio 22.94
Div & Yield 3.84 (3.59%)

Latest News

Hagens Berman Alerts Investors In AbbVie Inc. (ABBV) To The Firm's Investigation Of Possible Humira-Related Health Insurance Fraud And Disclosure Violations

Hagens Berman Alerts Investors In AbbVie Inc. (ABBV) To The Firm's Investigation Of Possible Humira-Related Health Insurance Fraud And Disclosure Violations

SAN FRANCISCO, Sept. 21, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in AbbVie Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against AbbVie Inc. - ABBV

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against AbbVie Inc. - ABBV

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AbbVie Inc.

AbbVie Receives Positive CHMP Opinion For A Novel, Chemotherapy-free Combination Of VENCLYXTO® (venetoclax Tablets) With Rituximab As A Treatment With A Fixed Duration For Patients With Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

AbbVie Receives Positive CHMP Opinion For A Novel, Chemotherapy-free Combination Of VENCLYXTO® (venetoclax Tablets) With Rituximab As A Treatment With A Fixed Duration For Patients With Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

- If approved by the European Commission (EC), VENCLYXTO® plus rituximab would be the first chemotherapy-free combination regimen with a fixed duration of treatment for patients with chronic lymphocytic leukemia who have received at least one prior therapy.

AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation Of AbbVie Inc. - ABBV

AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation Of AbbVie Inc. - ABBV

NEW YORK, Sept. 20, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of AbbVie Inc.

Investor Alert: Kaplan Fox Investigates AbbVie Inc.

Investor Alert: Kaplan Fox Investigates AbbVie Inc.

NEW YORK, Sept. 19, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.

AbbVie To Host Third-Quarter 2018 Earnings Conference Call

AbbVie To Host Third-Quarter 2018 Earnings Conference Call

NORTH CHICAGO, Ill., Sept.

The New #66 Most Shorted S&P 500 Component: AbbVie

The New #66 Most Shorted S&P 500 Component: AbbVie

The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

AbbVie Presents Upadacitinib Longer-Term (32-Week) And Patient-Reported Outcomes Data From Phase 2b Atopic Dermatitis Study At 27th European Academy Of Dermatology And Venereology (EADV) Congress

AbbVie Presents Upadacitinib Longer-Term (32-Week) And Patient-Reported Outcomes Data From Phase 2b Atopic Dermatitis Study At 27th European Academy Of Dermatology And Venereology (EADV) Congress

- Across all doses, a significantly greater proportion of patients who remained on upadacitinib showed continuous improvements in skin lesions and pruritus (itch) at week 32 compared to patients re-randomized to placebo[1]

AbbVie Announces Patient-Reported Outcomes Data From Three Pivotal Phase 3 Studies Of Risankizumab, Showing Significant Improvements In Health-Related Quality Of Life For Patients With Psoriasis

AbbVie Announces Patient-Reported Outcomes Data From Three Pivotal Phase 3 Studies Of Risankizumab, Showing Significant Improvements In Health-Related Quality Of Life For Patients With Psoriasis

- Pooled analyses from ultIMMa-1 and ultIMMa-2 studies showed significantly more patients treated with risankizumab were symptom-free (psoriasis symptom scale [PSS] score of 0) compared to placebo and STELARA® (ustekinumab) after 16 weeks and at one year (52 weeks) compared to ustekinumab[1]

Minimal Residual Disease Negativity Data, A Measure Of Undetectable Disease, Added To VENCLEXTA® (venetoclax Tablets) Label

Minimal Residual Disease Negativity Data, A Measure Of Undetectable Disease, Added To VENCLEXTA® (venetoclax Tablets) Label

- Minimal residual disease (MRD)-negativity is defined as having disease at a threshold of less than one chronic lymphocytic leukemia (CLL) cell per 10,000 lymphocytes in the blood or bone marrow[1]

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Sept.

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

Jim Cramer takes a look at United Parcel Service, TJX Companies, Anheuser-Busch InBev, Fiat Chrysler, AbbVie, Nvidia, Excelixis, Bank of America, Endo Pharmaceutical and more.

AbbVie Reinforces Leadership In Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio At The 27th European Academy Of Dermatology And Venereology (EADV) Congress

AbbVie Reinforces Leadership In Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio At The 27th European Academy Of Dermatology And Venereology (EADV) Congress

- Twenty-four presentations of HUMIRA® (adalimumab) and pipeline data showcase the breadth and depth of robust dermatology portfolio

AbbVie Announces Positive Topline Results From Phase 3 Extension Study Evaluating Investigational Elagolix In Women With Uterine Fibroids

AbbVie Announces Positive Topline Results From Phase 3 Extension Study Evaluating Investigational Elagolix In Women With Uterine Fibroids

- Study results (ELARIS UF-EXTEND) showed elagolix, in combination with add-back therapy, reduced heavy menstrual bleeding for up to 12 months

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against AbbVie Inc. (ABBV) And Lead Plaintiff Deadline - September 24, 2018

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against AbbVie Inc. (ABBV) And Lead Plaintiff Deadline - September 24, 2018

NEW YORK, Aug. 21, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie Inc.

10 Top Stocks With a History of Double-Digit Dividend Growth

10 Top Stocks With a History of Double-Digit Dividend Growth

Searching for dividends in this yield starved world? Check out these top 10 names.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of AbbVie Inc. - ABBV

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of AbbVie Inc. - ABBV

NEW YORK, Aug. 13, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc.

AbbVie, Greendot, Sherwin-Williams: 'Mad Money' Lightning Round

AbbVie, Greendot, Sherwin-Williams: 'Mad Money' Lightning Round

Jim Cramer takes a look at AbbVie, Greendot, Sherwin-Williams, Visteon, TransEnterix, Duke Energy, Buckeye Partners, Arch Coal and more.

More Than One Way to Win: Cramer's 'Mad Money' Recap (Thursday 8/9/18)

More Than One Way to Win: Cramer's 'Mad Money' Recap (Thursday 8/9/18)

Jim Cramer says that in good markets there are always multiple ways for investors to win.

Biotechs: Adding to Radius Health, Flexion

Biotechs: Adding to Radius Health, Flexion

This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.

The 5 Highest-Yielding 'Dividend Aristocrats'

This exclusive group of stocks is among the best when it comes to returning cash to shareholders and building wealth over time.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of AbbVie Inc. (ABBV)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of AbbVie Inc. (ABBV)

NEW YORK, July 31, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc.

13 Lucky Blue Chip Stocks to Buy With the Market Looking Shaky

13 Lucky Blue Chip Stocks to Buy With the Market Looking Shaky

Blue Chip stocks are the way to go right now. Here are several key names worth considering.

AbbVie Reports Second-Quarter 2018 Financial Results

AbbVie Reports Second-Quarter 2018 Financial Results

- Reports Second-Quarter Diluted EPS of $1.26 on a GAAP Basis; Adjusted Diluted EPS of $2.00 Reflects Growth of 40.8 Percent

Amazon Could Rise Another 15% From Here: Market Recon

Amazon Could Rise Another 15% From Here: Market Recon

This stock is still going wild after earnings.

TheStreet Quant Rating: B- (Buy)